Peptide Therapeutics Market Size Is Set To Grow By USD 17.85 Billion From 2024-2028, Increasing Prevalence Of Infectious Diseases To Boost The Market Growth, Technavio

Get a detailed analysis on regions, market segments, customer landscape, and companies
- Click for the snapshot of this report

Key Market Trends Fueling Growth

The peptide therapeutics market has experienced growth due to an increase in drug approvals, driven by strategic collaborations among market players. Companies form alliances for research and development of novel therapies to overcome technological and research challenges. For instance, AstraZeneca collaborated with Bicycle Therapeutics for the development of peptide-based therapies using Bicycle's technology. Bicycle Therapeutics will discover peptides for various indications, while AstraZeneca will develop and commercialize the drugs. AstraZeneca paid USD1 billion to Bicycle Therapeutics as part of the deal. Research organizations and market players also form alliances to develop peptide-based drugs. For example, AstraZeneca, Novo Nordisk, Zealand Pharma, and Zydus Cadila sponsor research programs with the Peptide Therapeutics Foundation. These collaborations are expected to significantly contribute to the growth of the global peptide therapeutics market.

The Peptide Therapeutics Market is experiencing significant growth due to the development of novel peptide-based drugs for various indications. Key trends include the use of peptides in treating alcohol abuse, high cholesterol, and infectious diseases. Innovative peptide synthesis techniques, such as solid-phase reactors and chemical functionalization, are improving the production of long peptides for oncology and other applications. However, challenges remain, including insolubility issues, waste generation, and expensive manufacturing equipment. Creative Peptides and other companies are addressing these challenges through advanced purification processes and 3D conformational structures. FDA approvals for peptide-drug conjugates, such as Adlyxin, Ozempic, and Xultophy, are driving growth in the metabolic segment. The cancer segment is also a significant market, with the development of peptide-drug conjugates and recombinant peptides. The biotech sector is a major player in the market, with a focus on biologics and small molecule-based interventions. The clinical benefits of peptide-based drugs, including target specificity and low toxicity, are driving demand in the pharmacological interventions space. The market is segmented into the oncology, metabolic, cancer, innovative, generic, in-house manufacturing, outsourcing manufacturing, parenteral route, pulmonary route, and hybrid technology segments. Applications in cardiovascular disorders and respiratory diseases are also expected to drive growth.

Research report provides comprehensive data on impact of trend. For more details-
Download a Sample Report

Market
Challenges

• Peptide therapeutics, including proteins like insulin and monoclonal antibodies (mAbs), present unique manufacturing challenges compared to small-molecule drugs. The complex process involves fermentation, clarification, separation, and purification steps, with each stage requiring precise temperature, pressure, and pH control. Insulin, a protein, is produced through fermentation, recovery, and purification processes, involving an understanding of living cells. However, the production process is time-consuming and costly due to the need for sterile facilities and large investments in biotechnology. Insulin's specific storage requirements add to its cost, with recommended temperatures between 36–46°F and protection from light and heat. The limited patient population and high R&D costs, which can range from USD650 million to USD750 million and take 8-9 years to complete, further increase the price. The cost burden is felt by end-users and insurers, potentially leading to treatment discontinuation and market growth hindrance. MAbs, another peptide therapeutic, face similar challenges due to their complex manufacturing process and high cost. The need for sterile conditions and product safety, ensuring freedom from contaminants, increases the production time and expense. The high cost of these therapies poses a significant challenge for market growth, as affordability remains a concern for both patients and insurers.
• Peptide therapeutics are gaining significant attention in the pharmaceutical industry due to their potential to treat various chronic diseases like cancer, metabolic disorders, hormonal therapy for diabetes and obesity, osteoarthritis, and osteoporosis. However, developing peptide therapy products comes with challenges. Clinical investigation is crucial to understand target affinity, toxicity profiles, and API stability. Novel leads require efficient drug delivery methods, such as peptide drug conjugates and cell penetrating peptides. Big
  pharma players and drug developers face hurdles in orphan drug designation, clinical studies, and dosing frequency. CROs and CMOs play a vital role in overcoming these challenges. Oral peptide delivery and peptide-based therapeutic vaccines are also being explored. Target disease indications include smoking cessation and pediatric patients. Pipeline molecules undergo rigorous testing to ensure safety and efficacy in disease management.

For more insights on driver and challenges
-
Download a Sample Report

Segment Overview

This peptide therapeutics market report extensively covers market segmentation by